Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of a weight loss drug, which has resulted in a significant drop in its stock price following the termination of a partnership with Novo Nordisk [1][4][5]. Group 1: Company Overview - Hims & Hers Health is a telehealth company that offers prescription and over-the-counter medications, as well as personal care products [3]. Group 2: Legal Allegations - The class action lawsuit claims that during the class period from April 29, 2025, to June 23, 2025, Hims & Hers made false or misleading statements and failed to disclose material facts regarding its business practices [4]. - Specific allegations include the deceptive promotion and sale of illegitimate versions of Novo Nordisk's weight loss drug, Wegovy®, which posed risks to patient safety [4]. - The lawsuit also suggests that these actions led to a significant risk of termination of the collaboration with Novo Nordisk [4]. Group 3: Impact of the Lawsuit - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing the deceptive practices as the reason, which resulted in a more than 34% decline in Hims & Hers' stock price [5].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its integration with the Food Safety Division of 3M Company, which misled investors about the progress of the integration [3]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from January 5, 2023, to June 3, 2025 [3]. - Defendants allegedly downplayed inefficiencies arising from the integration and assured investors of their commitment to resolving these issues quickly [3]. - Shareholders are encouraged to register for the class action by the deadline of September 16, 2025, to potentially become lead plaintiffs [4]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates and their regulatory prospects [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 24, 2023, to May 14, 2025 [3]. - Allegations include that Biohaven overstated the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the efficacy of BHV-7000 for bipolar disorder [3]. - The complaint claims that these misrepresentations are likely to have a significant negative impact on Biohaven's business and financial condition once revealed [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 12, 2025, to potentially be appointed as lead plaintiff [4]. - Registration will provide shareholders with portfolio monitoring software for status updates throughout the case [4]. Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its financial practices and operations, leading to significant stock price decline [1][4]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [3]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [3]. - The issues highlighted indicate weaknesses in Tempus' core operations and revenue prospects [3]. Group 2: Impact of Reports - On May 28, 2025, Spruce Point Capital Management issued a report raising multiple concerns about Tempus' management, operations, and financial reporting [4]. - The report pointed out that Tempus' actual AI capabilities may be overstated and that executives have ties to companies that have restated financial results [4]. - It also noted signs of aggressive accounting practices and issues with the AstraZeneca and Pathos AI deal that warrant further scrutiny [4]. - Following the release of this report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 [5].

Core Viewpoint - Over 10,000 European hotels have joined a collective lawsuit against Booking.com, seeking compensation for losses incurred due to a now-invalid clause that restricted competitive pricing [2][3]. Group 1: Lawsuit Details - The collective lawsuit targets Booking.com for damages from 2004 to 2024, claiming that the platform's clause put many hotels at a competitive disadvantage [2]. - The clause, which prohibited hotels from offering lower prices through their own or third-party channels, was ruled illegal by the European Court on September 19, 2024 [2]. - The deadline for hotels to join the lawsuit has been extended from July 31 to August 29 due to high demand for claims [3]. Group 2: Industry Impact - The lawsuit is supported by hotel industry associations from over 30 European countries, including Austria, Germany, Greece, and Italy [3]. - Despite dissatisfaction with Booking.com's practices, many hotels rely on the platform to expand their customer base [3]. - Booking.com holds a significant market share, accounting for 71% of the European market in 2023, with a notable decline in direct bookings from guests to hotels in recent years [3].

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/replimune-group-inc-loss-submission-form-3/?id=158801&from=4 DEADLINE: September ...

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fiserv, Inc. (NYSE: FI). Shareholders who purchased shares of FI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fiserv-inc-loss-submission-form/?id=158799&from=4 CLASS PERIOD: July 24, 2024 to July 22, 2025 ...

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements to investors while concealing material adverse facts regarding the company's capital allocation priorities, particularly concerning its dividend strategy [2][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Organon securities between November 3, 2022, and April 30, 2025, with a deadline of July 22, 2025, for investors to apply as lead plaintiffs [2]. - The lawsuit claims that the defendants made overwhelmingly positive statements while hiding the true state of Organon's priorities, especially regarding its debt reduction strategy after acquiring Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. Group 2: Stock Price Impact - Following the announcement of the lawsuit and the related disclosures, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [5]. Group 3: Investor Communication - Investors who suffered losses or have questions regarding their rights related to the lawsuit are encouraged to contact the law firm Bragar Eagel & Squire for more information [6].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations, leading to a significant drop in stock price [1][2]. Group 1: Allegations and Financial Impact - The class period for the allegations is from May 2, 2024, to May 6, 2025, during which Vestis Corporation allegedly provided overly positive statements while concealing material adverse facts about its business growth capabilities [2]. - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrew its revenue guidance for the full fiscal year, and provided lower-than-expected guidance for Q3 2025, attributing the poor performance to "lost business in excess of new business" and "lower adds over stops" [2]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by the deadline of August 8, 2025, to potentially become lead plaintiffs and receive updates on the case [3]. - Registration involves no cost or obligation, and participants will be enrolled in a portfolio monitoring system for status updates throughout the case lifecycle [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation for allegedly making materially false and misleading statements regarding its business and operations during the Class Period from January 29, 2024, to March 11, 2025 [1][3]. Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 2024, marking a 44% year-over-year decline [4]. - The company expressed substantial doubt about its ability to continue as a going concern for at least 12 months from the issuance of its 2024 financial statements [4]. Market Reaction - Following the announcement of poor financial results, iRobot's stock price fell by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [5]. - Analysts have downgraded iRobot's stock rating due to a bleak outlook, citing deteriorating business prospects and significant layoffs [5]. Legal Context - Investors who acquired iRobot securities during the Class Period are encouraged to contact Bragar Eagel & Squire, P.C. to discuss their legal rights [1][6].